Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.

Slides:



Advertisements
Similar presentations
Antiplatelet and anticoagulant therapy in stroke prevention
Advertisements

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Dr. Abdullah Ahmad Ghazi (R5) KSMC 8 May  TURP  gold standard in BPH  Using of A-Cog & A-Plt is increasing.  4% on A-Cog  37% on A-plt.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Treatment of Acute Pulmonary Embolism
Prophylaxis of Venous Thromboembolism
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.
Atrial Fibrillation Warfarin and its newer alternatives
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Secondary prevention after a TIA or ischemic stroke.
‘STROKE’ September 2010 Dr. Amer Jafar.
VCU Death and Complications Conference
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Management of Heart Disease in Pregnancy.  It is estimated that 1% to 3% of women either have cardiac disease entering pregnancy or are diagnosed with.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Intracerebral Hemorrhage
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Cardioembolic Stroke: Diagnosis and Management
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal.
Stroke in Children SICU meeting Ri 郭佑民. Recognition and Treatment of Stroke in Children [Clinical Guideline] Reviewed July 1, 2001 Child Neurology Society.
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Advances in Treatment for Acute Stroke
Warfarin in primary care
Copyright © 2012 American Medical Association. All rights reserved.
From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /
Volume 91, Issue 4, Pages (April 1987)
You can never be too Thin…. An Update on NOACs
Heart Valve Thrombosis & Neuro-Outcomes
Addressing the Challenges in Primary and Secondary Stroke Prevention
Ortho Warfarin Dosing Protocol
Anticoagulation in Atrial Fibrillation
Judith Misas, Pharm.D. Candidate PGY1 Residency Interview
Randomized Evaluation of Long-term anticoagulant therapY
Anticoagulation Prepared by Cherie Gan.
Aug, 2016.
Anticoagulation in Stroke.
Fibrillazione atriale
Selecting NOACs for High-Risk Patients
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Pradaxa Jeopardy Copyright 2001.
by Alex C. Spyropoulos, and James D. Douketis
How I treat cancer-associated venous thromboembolism
ACC 2003 Late Breaking Trials
Clive Kearon, Michael J Kovacs, Jim A Julian
RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.
Gianluigi Savarese et al. JCHF 2016;4:
Presentation transcript:

Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N

Complications A meta-analysis in not anticoagulated  Prosthetic valve thrombosis - 1.8% per patient-year (95% CI 0.9–3.0%).  Mechanical valve embolism resulting in death, stroke or peripheral ischaemia requiring surgery 4% per patient-year (95% CI 2.9–5.2%). This is reduced to 2.2% by antiplatelet drugs and 1.0% per patient-year with warfarin.  Risk of ICH increased by 7–10 fold, to an absolute risk of 0.3–1% per year. The mortality associated with oral anticoagulant related ICH is about 60%  The risk of ICH recurrence - 2% to 4% per patient-year.

Lobar hemorrhage or cerebral amyloid angiopathy - higher risk of anticoagulant related ICH recurrence than thromboembolic events – No anticoagulants. Deep hemispheric ICH/ hypertension that can be well controlled and high risk of thromboembolism – Anticoagulation

Risk factors - Recurrent bleed Amyloid angiopathy – Lobar haemorrrhage (4% Vs 2%) The presence and number of microbleeds on T2-wted gradient-echo MRI Apolipoprotein E genotype58 High Blood pressure High INR

Timing The European Stroke Initiative :patients with a strong indication for anticoagulation should be restarted on warfarin after 10 to 14 days, depending on the risk of thromboembolism and ICH recurrence. The American Heart Association : patients with a very high risk of thromboembolism for whom restarting warfarin is considered, warfarin may be restarted 7 to 10 days after ICH onset. The American College of Chest Physicians : start prophylactic dose heparin the day after an ICH - no clear guidance on restarting warfarin.

THANK YOU